ONCO-D-CLARE: False positives can be caused by peptides, HGH, GLP-1. 

If the Onco-D-Clare is positive and the Oncotrace is negative, this scenario CAN BE REVERSED. 

What are PMBCs?

PMBCs, or Peripheral Mononuclear Blood Cells, are blood cells that include lymphocytes (T cells, B cells, and natural killer cells) and monocytes. These cells have a round nucleus and are part of the immune system, playing a crucial role in immune responses.

What does it mean if the cMET is turned on?

Cancer transitions from mesenchymal to epithelial cells (MET). This is a critical phase in cancer metastasis, where cancer cells that have migrated through the body revert to an epithelial state to form new tumors. This process is essential for the establishment of secondary tumors at distant sites. Understanding MET mechanisms can help develop treatments that target cancer metastasis, reduce tumor growth at new sites, and overcome therapy resistance. The important C-met marker is the one on the Oncotrace.  The Onconomics Plus C-met marker is slightly different from the Oncotrace one.

If the C-met is turned on, the cancer will spread within 3 months.  However, you will not know when it was initially turned on.  This marker is grave if it is upregulated.

Can RGCC testing detect cancers of CNS origin?

No, Cancers of central nervous system (CNS) origin, such as gliomas or astrocytomas, generally cannot be detected by RGCC (Research Genetic Cancer Center) testing because of the CNS's unique biology and environment. RGCC testing focuses on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), primarily found in the bloodstream.

How many cancer cells make up a tumor?

It takes about 1 billion cancer cells to make up a 3-4mm tumor.

How long does it take for a 3mm tumor to develop?

It takes 7-10 years for a 3mm tumor to develop.

What does a tumor consist of?

• Cancer Cells (Parenchyma) are the malignant, rapidly dividing cells responsible for tumor growth, invasion, and metastasis.
• Stroma is the supportive tissue surrounding cancer cells, composed of fibroblasts, immune cells, blood vessels, and the extracellular matrix, which plays an active role in creating a microenvironment that supports tumor progression.

What is the goal of RGCC Therapies?

• Personalize treatment to match the genetic profile of the patient’s cancer.
• Improve treatment efficacy by targeting specific mutations, CTCs, and resistance factors.
• Reduce side effects and support overall health with integrative approaches.
• Prevent metastasis and recurrence by focusing on CTCs and cancer stem cells.
• Adapt treatments in real-time by monitoring disease progression and resistance.

Why would a patient need RGCC therapies after chemotherapy or radiation?

• Eliminate residual cancer cells, such as CTCs and cancer stem cells that may have survived initial treatments.
• Overcome treatment resistance by identifying and targeting mutations in resistant cancer cells.
• Reduce the risk of recurrence by targeting cells responsible for tumor regrowth.
• Personalize follow-up treatment based on the patient’s specific cancer profile.
• Support the immune system and overall recovery, potentially reducing side effects and toxicity.
• Monitor disease progression to detect and address any early signs of recurrence or metastasis.
• Target and prevent metastasis, offering a more comprehensive approach to long-term cancer management.

What test should be done if the Onco-D-Clare is positive?

Oncotrace testing should be ordered to look for CTCs indicating that the cancer is outside the tissue.  If there are no CTCs, lifestyle changes can reverse a positive Onco-D-Clare.

How do you properly order the Oncotrace?

Oncotrace testing should be ordered by declaring the type of cancer to be tested.  If the origin of the tumor is unknown, order a CUP (cancer of unknown primary) for an undetermined primary.

CTC’s can be used for staging:

• <2.7= Stage 1
• 7-3.7= Stage 2
• 7-4.25= Stage 3

What can cause false negative results?

Contamination of the blood draws causes false negative results.  You should consider contamination if the CD31 and PanCK are positive on the Oncotrace.

CTC goal: 0 can be achieved.  However, if you have less than 1.4, remission is considered.

Use of AcGH for determining origin:  if the cancer is DNA-based and not genetic-based, this will determine the origin.  This is the reason is only determined in 70-80% of cancers.

—---------------------

MEDICATION AND SUPPLEMENT

Methylene blue should be rotated. If a patient follows a monthly protocol, it will be prescribed every other month or every two months if the patient follows a two-month protocol.

Natural Substances that DO NOT work well together

• Genistein – Do not mix with Quercetin during the same month
• Vascustatin – Do not mix with Genistein during the same month
• Artecin – Do not use with Super Artemisinin during the same month
• Poly MVA – Do not mix with Lycopene on the same day
• IV – C – Do on opposite days of PolyMVA - or at least 6-8 hours after IV
• Salvestrol – Do not take with Resveratrol during the same month
• Artecin or Super Artemisinin - Do not do oral vitamin C on the same days
• No ECGC on Days of IV Vit C
• Do not use C-Statin and Vacustatin in the same month
• No resveratrol with hormone-receptive cancers

—--------------

BIOMARKERS:

HSP shows the effectiveness of hyperthermia therapy in that the cells can’t repair the damage caused by hyperthermia. The higher the - number, the better, but you want the HSP90 to be at least -20 for hyperthermia, which is the most effective.

Prostate cancer behaves well as long as it stays hormone-positive and multi-focal. This is why Gleason's score matters. PSA and PSMA follow a pattern. Treatment with hormone suppression is essential.  PSA and/or PSMA when dim means metastasis is happening. It almost always goes straight to the bones. Once Dim (refractory status) needs to be treated with cytotoxic agents. Hormone suppression alone will not work. PSMA is not soluble, so it’s more accurate with tissue. PSA is soluble and free-floating, so it’s easier to measure with blood. A regular PSA includes carrier proteins. It will also measure lots of die-off so that it will show false elevation. We need to run a free PSA, not a total. We need both tissue and liquid biopsies for a complete picture.

If the GST marker is >15%, do not order methylene blue, ozone, high-dose vitamin C, NAC, or glutathione

If the MDR1 >40%, then you must rotate natural monthly not bi-monthly

If the SOX2 + OKT-4 are positive (Oncotrace), the patient is at a high risk of recurrence

If the CD19 marker is positive (Oncotrace,) lung cancer is present

If the CD31 is positive, you must assume the sample was contaminated with endothelial cells

If you have a patient who starts with anaplastic markers and wants to start TRT, you can use the PSA as a marker of response to the TRT.  PSA should be measured at 6 weeks post-starting TRT

Important markers to consider:

• C-met
• PTEN
• COX2- >25%
• IGF-1/IGF2
• NR3C4-A|NR3C4-B
• TGF-B
• CXCR4|CXCR12
• VEG-F
• c-MET
• 67LR (want this downregulated)
• KISS-14 (want this upregulated)
• P27 (want upregulated)
• MMP
• NM23

How to see improvements:

• EpCAM (Oncomonics Plus) same or higher
• PanCK is the same or higher
• CMET is negative
• CTC’s diminish in numbers
• EpCam+ on Oncotrace diminishes in numbers
• If CTCs go down and EpCAM+ stays up, you are killing weaker cancer cells

If your CTCs go up, you must consider another cancer.

NO CHELATION DURING Q RESTRAIN (SOT) THERAPY: IT COULD BIND TO THE SOT AND INACTIVATE IT

If a patient cannot or will not use the steroids with the Q Restrain (SOT), a waiver must be signed acknowledging the effectiveness may not be as expected.  The purpose of the steroid is to tighten the “leaky junctions” in the veins.  The SOT is so tiny it can escape via these junctions.  Another benefit of the steroid is that it prevents any kind of allergic reaction to the SOT.